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Introduction
Isosexual precocious puberty is the appearance of physical signs of sexual development in keeping with the phenotypic gender of the child prior to the earliest accepted age of sexual maturation. Precocious puberty is of concern because of the underlying disorders that may cause premature sexual development, the short adult stature that may result from rapid skeletal maturation attributable to early secretion of sex hormone, and the psychosocial difficulties that the sexually precocious child may encounter.
Normal Puberty

PHYSICAL DEVELOPMENT
The Sexual Maturity Rating (SMR) (Tanner) stages of sexual development are described in Tables 1 and 2 . In girls, breast budding (thelarche) is usually the first sign of puberty; pubic hair growth (pubarche) is the initial pubertal sign in 15% of girls. Menarche occurs an average of 2 years after thelarche (range, 1 to 5 y), and peak height velocity (PHV) is reached at 12 years in girls immediately prior to menarche. Pelvic ultrasonography demonstrates a progressive increase in uterine length and ovarian volume during sexual maturation, correlating with breast growth and serum estradiol concentrations, although these stages overlap substantially. In addition to an increase in volume, the ovarian echogenic pattern varies with advancing puberty as multiple, initially small and then somewhat larger, follicular cysts appear and regress; in the late adolescent female, a multicystic ovarian sonographic pattern is common.
In boys, the earliest physical sign of puberty is testicular enlargement (long diameter Ͼ2.5 cm, volume Ͼ4 mL). Pubertal development progresses at a relatively slow pace through SMR stage III male genital development and then accelerates; approximately 4 years elapse between genital stages II and V. PHV is achieved at the average age of 14 years.
There is substantial variation in the onset and duration of puberty for both genders. Those in whom the timing and progression of sexual maturation are "shifted to the left" experience early puberty, at times a familial characteristic. When sexual development begins before the youngest accepted age, that child has precocious puberty.
In girls, the age before which pubertal onset has been considered precocious long has been 8 years. However, new data indicate that breast development before 6 to 7 years in Caucasian girls and before 5 to 6 years in AfricanAmerican girls is a more appropriate criterion. Thus, it recently has been reported that at 3 years of age, 3% of African-American and 1% of Caucasian girls have either thelarche or pubarche, with the percentages increasing to 5.7% and 1.9% at 5 years and to 27.2% and 6.7% at 7 years, respectively ( Fig. 1) . At each age, the sexual maturation of African-American females is more advanced than that of Caucasian females. Menarche occurs in 2.3% of African-American females by 7 years of age compared with 0.2% of Caucasian females; by 11 years the percentages are 27.9% and 13.4%, respectively. However, mean menarcheal age has not changed (African-American, 12.2 y; Caucasian, 12.9 y). On the other hand, African-American and Caucasian males appear to mature at comparable ages. Sexual development before 9 years of age is considered precocious in boys of either ethnic background.
HORMONES
Skeletal maturation (bone age) and increase in bone mineralization parallel the progression of chronologic age under the influence of growth and thyroid hormones, estrogens, and androgens. Estrogen is responsible for epiphyseal fusion and attainment of adult bone mineral density. As measured by magnetic resonance imaging, the height of the anterior The onset of puberty is characterized hormonally by an increase in the frequency and amplitude of the GnRH "pulse generator" that is reflected by a rise in basal serum LH and FSH concentrations, augmentation of nocturnal LH secretion, and an increase in the LH secretory response to exogenous GnRH. In females, the FSH secretory response to GnRH declines with advancing pubertal development, and the GnRH-stimulated peak LH/FSH ratio increases (Tables 3 and 4) . Gonadarche is manifested by increased secretion of estradiol in girls and testosterone in boys. In females, the cyclic pattern of HPG function develops as the processes of ovarian oogenesis and ovulation mature. There is also a peripubertal increase in the secretion of the adrenal androgens dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), with adrenarche usually beginning between 6 and 8 years in both genders. Adrenarche and gonadarche may be dissociated in several disorders of puberty, including primary hypogonadism (Turner syndrome) and isosexual precocity. During puberty there is a marked increase in the spontaneous secretion of growth hormone (GH) as well as in the GH secretory response to provocative stimuli and in serum concentrations of insulin-like growth factor-I.
Causes of Isosexual Precocious Puberty
Isosexual precocious puberty is several-fold more common among girls than boys. Approximately 50% of children who have isosexual precocity have true and complete central precocious puberty (CPP) ( Table  5 ). In CPP, pubertal development is driven by GnRH, as the "restraint" placed on the HPG axis by higher CNS centers is removed, which is the same mechanism that brings about normal sexual development. CPP may be due to congenital anomalies; infectious, neoplastic, or traumatic insults to the CNS; or treatment of long-standing sex hormone exposure due to pseudoiso- Familial male-limited precocious puberty (testotoxicosis) is due to a germ-line mutation in the LH receptor that renders it constitutively active; that is, it behaves as if it were being stimulated by its natural ligand (LH) and, thus, "turns on" Leydig cell testosterone synthesis. The McCune-Albright syndrome is due to a germ-line mutation that leads to a constitutively active G alpha s subunit of the guanosine triphosphate binding protein, the membrane-bound signaling molecule linked to the LH receptor, and results in both Leydig cell synthesis of testosterone and granulosa cell production of estradiol. Ovarian cysts, granulosa, and Leydig cell gonadal tumors also secrete sex hormones independently of gonadotropin control and are, at times, due to somatic tissue-specific mutations in the LH receptor or the G alpha s subunit of the G-protein.
Congenital adrenal hyperplasia due to deficiency of either 21-or 11 beta-hydroxylase leads to excessive secretion of testosterone and pseudoisosexual precocious puberty in males. In some girls who have primary hypothyroidism, thelarche and uterine bleeding occur; in males, macro-orchidism may result, although excessive phallic and pubic hair growth seldom are seen. In this complex, precocious puberty may be Incomplete forms of isosexual precocious puberty are relatively benign. As noted, the HPG axis is active even in prepubertal girls; if an ovarian follicle secretes sufficient estrogen, breast and uterine endometrial growth may be stimulated, leading to premature thelarche or uncommonly premature menarche, which are both self-limited and nonprogressive states. Postnatally, in utero breast development usually disappears within several weeks after birth, but occasionally it may persist for as long as 8 months. Approximately 10% of children who have apparent premature thelarche progress to CPP, particularly if breast growth begins after 2 years of age. Premature pubarche, which most often is due to an early increase in adrenal androgen secretion (premature adrenarche), is followed by functional ovarian hyperandrogenism in 20% of affected young women. 
Evaluation
CLINICAL EVALUATION
A thorough historical review and complete physical examination are the first steps in evaluating the child who has precocious puberty (Table  6 , Figs. 2 and 3) . If the primary concern is early thelarche, it is helpful to determine whether neonatal breast development has persisted or regressed only to recur later; the latter suggests a "new" process. The growth rate in the child who has CPP or pseudoisosexual precocious puberty usually is rapid, and height rises to a higher growth percentile than occupied previously. Children who have incomplete forms of precocious puberty usually continue to grow steadily in an established channel. It is essential to learn if a sibling had ambiguous genitalia (ie, congenital adrenal hyperplasia) or if the father, grandfather, or uncle was sexually precocious (familial male-limited sexual precocity). Height, weight, and head circumference are plotted (increasing head circumference may suggest hydrocephalus); blood pressure is recorded (an elevated blood pressure may suggest congenital adrenal hyperplasia due to deficiency of 11 beta-hydroxylase); sexual maturity is rated; and signs of systemic disease are sought. In girls, it is necessary to distinguish between the dense, irregular consistency of ductal breast tissue and the soft, smooth consistency of increased subcutaneous fat and between the reddish, less moist vaginal mucosa and small labia minora of the prepubertal girl compared with the pale, moist appearance of pubertal vaginal mucosa and elongated labia minora. In boys, measurement of phallic and testicular dimensions and careful palpation of the testes are crucial; testicular volume is disproportionately greater than phallic size, as in normal puberty, in males who have CPP (and some who have primary hypothyroidism). In males who have pseudoisosexual precocious puberty, penile dimensions are disproportionately greater than testicular size. Usually the testes are prepubertal in size (long diameter Յ2 cm, volume Յ3 mL) and consistency (indicative of an extragonadal source of androgen such as the adrenal or a teratoma). Sometimes they may be modestly and symmetrically enlarged (2.5 to 3.5 cm, 5 to 6 mL) (familial male-limited precocious puberty, hCG-secreting tumors), and rarely they are asymmetrically enlarged, possibly with the presence of a palpable mass (Leydig cell or adrenal rest tumor). In girls who have isolated vaginal bleeding, it is necessary to exclude local causes, such as a foreign body, vaginitis, and neoplasia.
LABORATORY ASSESSMENT
The next step in the evaluation is governed by the physical findings and the child's bone age (hand/wrist radiograph) (Figs. 2 and 3) . Advanced skeletal maturation reflects long-standing sex hormone action and possible developmental maturity of the CNS and HPG axis. In most patients who have CPP or pseudoisosexual precocious puberty, the bone age is more than 2 years in advance of the chronologic age. In children who have incomplete forms of precocious puberty, bone age more closely approximates or is only slightly more mature than the chronologic age. When the diagnosis of the McCune-Albright syndrome is suspected, a skeletal survey or tech- (Table 7) . In girls who have isosexual precocity, basal LH levels in excess of 0.3 IU/L are found primarily in CPP. If necessary, the prepubertal or pubertal state of the HPG axis may be assessed further by determining the gonadotropin secretory response to GnRH. A serum LH concentration of 8 IU/L 40 minutes after the subcutaneous administration of 100 mcg of GnRH is consistent with CPP. Suppressed or prepubertal GnRH-stimulated LH secretion is consistent with either pseudoisosexual or incomplete forms of sexual precocity. However, as with all gonadotropin assays, there is overlap between basal and post-GnRH LH and FSH values among prepubertal and early pubertal subjects. Therefore, basal and post-GnRH LH and FSH measurements must be interpreted in relation to the clinical findings, bone age, and sex hormone levels.
Basal serum concentrations of estradiol frequently are low (Ͻ10 pg/mL) or appropriate for the SMR (Tanner) stage of breast development in girls who have CPP; in those who have estrogen-secreting ovarian cysts or granulosa cell tumors, estradiol levels often exceed 100 pg/mL. Serum concentrations of anti-müllerian hormone often are increased in patients who have ovarian granulosa cell tumors. Ultrasensitive assays for estrogen are being developed that may help distinguish between prepubertal girls and those who have various forms of precocious puberty. In girls who have CPP, pelvic ultrasonography reveals a maturational increase in uterine length and ovarian volume and echogenic pattern (Ͼ6 cysts Ͼ4 mm in diameter). Ovarian cysts are demonstrated easily by this technique unless the cyst has ruptured and disappeared by the time of the examination. Because it is difficult to interpret pelvic ultrasonograms in prepubertal and pubertal girls, the reader should be experienced. In boys who have CPP, serum testosterone values are appropriate for the SMR (Tanner) stage of male genital development and substantially elevated in those who have testicular neoplasms. Magnetic resonance imaging of the CNS is essential in all patients who have CPP to identify any specifically treatable CNS lesion.
Boys who have 21-hydroxylasedeficient congenital adrenal hyperplasia will exhibit elevated serum concentrations of 17 alphahydroxyprogesterone that decline after administration of cortisol. In those who have deficiency of 11 beta-hydroxylase, serum levels of 11-deoxycortisol are increased. Patients who have virilizing adrenal tumors have markedly elevated serum levels of DHEA and DHEAS. Those who have familial malelimited precocious puberty often present with a positive family history, symmetrically but only slightly (5 to 6 mL) enlarged testes, pubertal serum testosterone levels that increase further after hCG administration, prepubertal basal and postGnRH concentrations of LH and FSH, and testosterone secretion that is not suppressible by GnRH agonists. Leydig cell tumors usually are identified as unilateral testicular masses; testosterone concentrations are pubertal and nonsuppressible.
In children who have premature thelarche (or rarely, premature menarche), the bone age is similar to or only modestly advanced (Ͻ2 y) over chronologic age; serum levels of LH, FSH, and estradiol are within the prepubertal ranges; and pelvic ultrasonography reveals prepubertal uterine and ovarian sizes and echogenic patterns (Ͻ3 cysts Ͻ5 mm in diameter). Clinical judgment dictates the extent of evaluation of a female infant who has suspected premature thelarche, with watchful observation often being the most appropriate. For girls who have vaginal bleeding for which a local cause cannot be identified readily, pelvic ultrasonography is required to eliminate an intravaginal neoplasm.
For children who have premature pubarche, bone age is usually less than 2 years in advance of chrono- 
Management and Prognosis
Effective management of the child who has isosexual precocious puberty depends on accurate identification of the cause and assessment of its significance. In children who have CPP due to a specifically remediable anatomic abnormality of the CNS, primary attention is focused on management of the underlying disorder; the effect of its successful treatment on the course of CPP then is monitored because this process may ameliorate.
IDIOPATHIC CPP
In those who have idiopathic CPP or puberty associated with a hypothalamic hamartoma or other form of CPP for which primary therapy is not available (eg, the child who has pseudoisosexual precocity that during or after treatment has evolved into CPP), the pubertal HPG axis may be inhibited by the administration of a long-acting agonist of GnRH (GnRHa). The most commonly employed agent is depotleuprolide (0.3 mg/kg intramuscularly every 3 to 4 weeks). Longacting forms of GnRHa are more effective in suppressing the HPG than are shorter-acting forms administered several times daily by intranasal inhalation or subcutaneous injection. The use of GnRHa (a stimulus to LH and FSH secretion) in children who have CPP may seem paradoxical because an intravenous pulse of GnRH stimulates gonadotropin secretion. However, when GnRH is administered as a constant infusion over several hours, gonadotropin secretion initially is stimulated and then inhibited. This inhibition is attributed to downregulation of gonadotroph membrane GnRH receptors and alterations in intragonadotroph synthesis of the gonadotropins. The same process occurs when long-acting GnRHa is administered by intramuscular injection.
In some girls who have CPP, vaginal bleeding may occur 2 weeks after the first injection of GnRHa but usually not thereafter. In the majority of children who have CPP, suppression of HPG function is complete within 4 to 8 weeks after initiation of therapy. The continued efficacy of GnRHa therapy is monitored clinically (decline in growth rate, regression or lack of progression of physical signs of sexual maturation, amenorrhea), radiographically (decreased rate or even arrest of bone age advancement), and hormonally (basal estradiol or testosterone and post-GnRH peak LH concentrations at 3-month intervals). Although GnRHa effectively suppresses HPG function in children who have CPP, it is important to identify the child in whom treatment is necessary and appropriate. Most boys who have CPP merit therapy with GnRHa because their bone age usually is markedly advanced and pubertal development is progressive. For many girls who have CPP, sexual maturation progresses slowly; their bone age is not greatly in advance of chronologic age, the change in the height age/bone age ratio is Ͼ0.9 per year, growth rate is normal, and predicted adult height is compatible with genetic potential and does not decline during observation. In such children, reassurance and observation as they fade into early-normal puberty are appropriate. Nevertheless, it is necessary to follow all girls who have CPP because occasionally a child who has the apparently slowly progressive form may experience rapid acceleration of skeletal maturation and develop criteria for treatment with GnRHa. Several questions should be considered before placing the child who has CPP on GnRHa (Table 8) . If the majority of answers to these questions are positive, treatment with GnRHa should be initiated. Depending on the age, skeletal maturation, and hormonal data, it often is reasonable to follow the girl who has idiopathic CPP for 6 months to document the rate of pubertal progression before deciding whether GnRHa therapy is appropriate.
Administration of GnRHa leads to cessation of menses in girls and regression or halt in the progression of sexual characteristics in both genders. The rates of linear growth and skeletal maturation decline. With GnRHa treatment, the adult height of children who have CPP now is 8 to 12 cm greater than that realized before the availability of this therapeutic agent. Trials of combined administration of GnRHa and growth hormone have been initiated with initially encouraging increases in predicted adult height. However, the long-term effects of combined treatment on achieved adult height and psychosocial advantage that it may provide have yet to be defined. Therapy with GnRHa usually is halted between 11 and 12 years of age in girls and 12 and 13 years of age in boys as age peers achieve their pubertal development. After discontinuing GnRHa, the HPG rapidly returns to the pubertal state; menses usually occur within 6 to 18 months after stopping GnRHa injections.
PSEUDOISOSEXUAL PRECOCIOUS PUBERTY
In patients who have pseudoisosexual precocious puberty, the primary disease must be treated. Gonadal, adrenal, and other tumors are excised; patients who have classical and nonclassical forms of congenital adrenal hyperplasia receive cortisol; and those who have hypothyroidism are treated with thyroxine. Ovarian cysts associated with thelarche and elevated estrogen levels may be managed expectantly; the cyst often regresses spontaneously. In boys who have familial malelimited precocious puberty or the McCune-Albright syndrome, testosterone synthesis may be inhibited by ketoconazole (an inhibitor of 17 alpha-hydroxylase/17-20 lyase). Testolactone, an aromatase inhibitor, may be useful temporarily in girls who have hyperestrogenemia due to the McCune-Albright syndrome. After suppression of gonadotropinindependent sex hormone secretion, some patients who have pseudoisosexual precocious puberty may have the condition evolve into CPP, particularly if their bone ages are in the pubertal range. These children then may be treated effectively with GnRHa.
PREMATURE THELARCHE AND ADRENARCHE
In the majority of girls who have premature thelarche, breast growth regresses within 4 years after it first developed. However, CPP evolves in approximately 10% of children who have apparent premature thelarche. Girls who have premature thelarche may have several monthly menstrual periods before menses disappear. In general, the parents of these girls may be reassured and the child observed. Most boys and many girls who have premature adrenarche experience no long-term adverse effects; because of the high frequency (20%) of functional ovarian hyperandrogenism, all girls who have premature adrenarche require follow-up into young adulthood.
PSYCHOSOCIAL ASPECTS
Children, particularly boys, who have markedly advanced sexual development tend to be shy and withdrawn when in the company of their age peers and may seek older companions. Because of their large size and mature physical appearance, more advanced sexual and maturational behavior may be expected from such children by adults. However, the intellectual, emotional, psychosocial, and psychosexual development of these children usually is age-appropriate. It is essential to provide counseling and support to parents and teachers in regard to the need to expect age-(not appearance-) appropriate behavior. It also is crucial to provide safeguards to prevent sexual abuse of the child who has CPP and is potentially fertile. There appear to be few longterm adverse psychosocial or educational consequences of isosexual precocity. When pubertal advance is halted or regresses during GnRHa treatment, some of the behavioral concerns also recede. 
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